Evaxion Biotech AS (EVAX)

NASDAQ
Currency in USD
1.770
+0.020(+1.14%)
Closed
After Hours
1.720-0.050(-2.825%)
EVAX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
1.7001.850
52 wk Range
1.67022.048
Key Statistics
Edit
Prev. Close
1.77
Open
1.8
Day's Range
1.7-1.85
52 wk Range
1.67-22.048
Volume
83.55K
Average Volume (3m)
2.42M
1-Year Change
-88.69%
Book Value / Share
0.07
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
EVAX Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
13.250
Upside
+648.59%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year
Show more

Evaxion Biotech AS Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.

Compare EVAX to Peers and Sector

Metrics to compare
EVAX
Peers
Sector
Relationship
P/E Ratio
−1.0x−2.3x−0.5x
PEG Ratio
−0.010.020.00
Price/Book
149.9x0.5x2.6x
Price / LTM Sales
3.4x6.6x3.0x
Upside (Analyst Target)
-434.1%57.1%
Fair Value Upside
Unlock26.9%10.6%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 13.250
(+648.59% Upside)

Earnings

Latest Release
May 09, 2024
EPS / Forecast
-- / -0.48
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

FAQ

What Is the Evaxion Biotech AS (EVAX) Stock Price Today?

The Evaxion Biotech AS stock price today is 1.77.

What Stock Exchange Does Evaxion Biotech AS Trade On?

Evaxion Biotech AS is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Evaxion Biotech AS?

The stock symbol for Evaxion Biotech AS is "EVAX."

What Is the Evaxion Biotech AS Market Cap?

As of today, Evaxion Biotech AS market cap is 11.09M.

What is Evaxion Biotech AS Earnings Per Share?

The Evaxion Biotech AS EPS is -12.40.

From a Technical Analysis Perspective, Is EVAX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.